Microdosing Iboga: What We Know

Microdosing arrived in the iboga world by analogy. People microdose psilocybin and LSD, so people microdose iboga. The analogy is the problem, because the pharmacology does not transfer.

Start with the size of the evidence

Zero placebo-controlled studies. Not few, zero. Every placebo-controlled microdosing trial ever published concerns LSD or psilocybin.

A 2026 scoping review of ibogaine across psychiatric disorders puts the position in one sentence: microdosing and escalating sequential protocols remain experimental, lack standardised definitions, and are supported only by preliminary observational data.

Read the middle clause again. There is not an agreed definition of what a microdose of this substance even is.

The human record is two publications.

A woman of 47 with bipolar II took two 4 mg capsules twice daily for sixty days, that is 16 mg a day. Her depression, anxiety and hopelessness scores fell steadily and no manic switch occurred. She also stopped her mood stabilisers and her antidepressant on her own during the study, which is confounded with the result. One co-author is a consultant for a pharmaceutical company. The material came from a commercial vendor and its purity was not independently verified.

Three people with brain injury took root bark at 0.1 to 1 gram a day, four days on and three off, for six weeks, alongside weekly psychotherapy and supplements. The authors’ own conclusion is unusually well calibrated: the findings do not establish causality or any iboga-specific efficacy, and should be read in the context of multimodal exposure and substantial methodological limitations.

Four people, in total, in the world’s published literature.

The half-life problem

This is the argument most likely to be new to someone reading about microdosing, and it is the one that matters.

Ibogaine is converted to noribogaine, which is active in its own right and blocks the cardiac potassium channel slightly harder than the parent compound does. In an ascending-dose study of 36 healthy volunteers, noribogaine’s mean half-life was 28 to 49 hours.

Grams of bark are not milligrams of drug

The brain-injury case series did something almost nobody does: it had the material assayed. The root bark used contained about 3.8 per cent ibogaine by mass.

That figure is useful in both directions. It lets you see that a gram of bark delivers tens of milligrams of ibogaine rather than a gram of it. And it is one sample, analysed once. Alkaloid content varies between plants, between parts of the plant and between suppliers, which is why buying iboga online is a page on this site.

Anyone describing a bark dose in grams is describing a volume of plant material, not a dose of a drug.

The interaction nobody mentions

Microdosing is done at home, by people who are usually taking something else.

In 21 healthy volunteers given a single 20 mg dose, which is squarely in the microdosing range, six days of paroxetine beforehand roughly doubled exposure to ibogaine and its metabolite. The study found the 20 mg dose safe and well tolerated, and it reports no psychoactive effect as an outcome at all.

The brain-injury case series screened out participants taking SSRIs, and screened out cardiac conditions. That is what careful looks like, and it is not what a home protocol looks like.

Ibogaine drug interactions sets out which drugs and why.

What the wider microdosing literature suggests

Since there is nothing for iboga, the honest move is to borrow carefully and label the borrowing.

A double-blind placebo-controlled study of psilocybin microdosing in 34 people found acute effects significantly stronger on the active dose only among participants who correctly identified which condition they were in. The authors conclude that expectation underlies at least some of the anecdotal benefits.

A review of 19 placebo-controlled studies concluded that it is not yet possible to determine whether microdosing is a placebo. Its authors disclose funding from several psychedelic companies, which we note as we would for any study on this site. And a 2025 review of 57 studies found the familiar pattern: observational studies report benefits, experimental trials tend toward null findings.

That is evidence about other drugs. Iboga is not a 5-HT2A psychedelic and the mechanisms are not shared. It tells you what happens when this question is asked properly of a similar practice, and the answer has so far been unflattering.

Where this leaves you

If someone tells you microdosing iboga is a gentler way in, three things are true at once.

The peak concentration from a small single dose is genuinely lower, and peak concentration is what drives the cardiac risk on a single occasion.

The metabolite accumulates over days, and nobody has measured what a repeated schedule does to steady-state levels or to the QT interval.

And the efficacy question is entirely unexamined. Four people, both reports confounded, no control group, no blinding, no standard definition of the practice.

That is not an argument that it does nothing. It is an accurate description of how little anyone knows, offered against a lot of confident writing to the contrary.